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Streszczenie
Wstęp
W warunkach polskich leczenie hormonem wzrostu 
pacjentów w wieku rozwojowym prowadzone jest od 
1964 roku. Do 1993 roku terapia ta była prowadzona w 
sposób przerywany, co wynikało z okresowej dostępności 
leku. Dane na temat tak prowadzonego leczenia 
wskazywały, że wzrost ostateczny chorych jedynie 
w części przypadków osiągał wartości zbliżone do trzeciego 
centyla. Od 1995 roku hormon wzrostu stosowany jest 
w sposób ciągły, co umożliwia podsumowanie efektów 
terapii, zarówno co do osiąganego tempa wzrastania jak 
i uzyskiwanego wzrostu ostatecznego.
Materiał i metody
Badaniami objęto 117 dzieci i młodzieży obojga płci, 
w wieku od 4,6 do 18,1 lat z rozpoznaną somatotropinową 
lub wielohormonalną niedoczynnością przysadki, 
leczonych hormonem wzrostu. U wszystkich badanych 
analizowano szybkość wzrastania i osiągnięty wzrost 
ostateczny.
Wyniki
W ciągu pierwszych 6 miesięcy terapii hormonem 
wzrostu szybkość wzrastania osiągała 10,4 cm/rok 
u chłopców i 10,0 u dziewcząt i nie wykazywała zależności 
od statusu dojrzewaniowego. W drugim półroczu 
leczenia szybkość wzrastania nieznacznie obniżała się. 
W dalszych latach terapii, szybkość wzrastania wyraźnie 
zmniejszała się, co było widoczne zwłaszcza u dziewcząt. 
U 93% chorych, którzy zakończyli leczenie, osiągnięty 
wzrost ostateczny nie odbiega w sposób istotny od 
wzrostu prognozowanego.
Wnioski
1. Szybkość wzrastania w pierwszym półroczu terapii 
hormonem wzrostu była 3-krotnie wyższa niż przed 
leczeniem.
2. W drugim półroczu leczenia tempo nieznacznie 
obniżało się.
3. W dalszych latach następował wyraźny spadek 
szybkości wzrastania.
4. Osiągnięty u większości leczonych wzrost ostateczny 
nie odbiega w sposób znaczący od wzrostu 
prognozowanego.
(Endokrynol Pol 2005; 2(56): 246-251)
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wzrostu, leczenie hormonem wzrostu, szybkość 
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Summary
Introduction
In Poland treatment with growth hormone of adolescent 
patients dates back to 1964. Till 1993 the therapy was 
conducted in an interrupted manner, depending on the 
periodic availability of the drug. The data form such 
forms of therapy suggested that the end height within 3rd 
centile was achieved only by a portion of treated patients. 
Since 1995 the growth hormone is used in continuous 
therapy, which allows to sum up the effects of the 
therapy, including the growth rate and end height.
Material and methods
A total of 117 children and adolescent of both sexes, 
aged 4.6 to 18.1 years, with diagnosed somatotropic or 
multihormonal pituitary insufficiency were included in 
the study. All of them were treated with growth hormone 
and had an analysis of growth rate and end height.
Results
In the first 6 months of growth hormone treatment the 
growth rate achieved 10.4 cm/year in boys and 10.0 in 
girls and showed no correlation with maturation status. 
In the second half of the year the growth rate declined 
slightly. During the remainder of the therapy the growth 
rate markedly declined, and this effect was most notable 
in girls. In 93% of patients after the end of therapy the 
final height was no different than the expected height.
Conclusions
1. The growth rate in first half a year of the treatment was 
3 times higher than before the beginning of therapy.
2. In the second half of the first year the growth rate 
slightly declined.
3. In following years the growth rate declined notably.
4. The final achieved height in most of the patients does 
not differ from the prognosed height.
Key words: growth hormone, growth hormone deficit, 
growth hormone therapy, growth rate, final height
(Pol J Endocrinol 2005; 3(56): 246-251)
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Introduction
For many years, that is from the first time the 
treatment with growth hormone was introduced 
for therapy of patients with pituitary deficiency 
there is an ongoing debate about the effects of such 
treatment [1, 2]. The differences in achieved rates 
of growth, dosage and final stature are caused by 
both the changes in the treatment methods that 
have been seen for all these years (e.g. dosing, 
frequency of injections) but also the time during 
which the treatment was conducted. From 2, 3 injec-
tions per week we have switched to daily injec-
tions; a new, optimal dose of the drug was accepted 
[1, 2, 3, 4]. It seems then that there is no time like 
present to sum up the efficacy of this treatment 
and finding final answers for many troubling 
questions. In some European cities and in America 
there are some papers that deal with this subject. 
They are very valuable, because besides many years 
of experience they have an additional support of 
large databases encompassing many patients (e.g. 
KIGS Data-Base). In Poland Romer performed 
similar study, based on the effects of treatment of 
a large number of children hospitalized in Children 
Health’s Center [1]. Presented data encompasses 
children and adolescents treated in previous years 
when, during therapy there were unexpected termi-
nations of treatment of different durations, caused 
by administrative factors. It rendered the full evalu-
ation of treatment effects impossible. The growth 
hormone treatment was introduced in 1995 and is 
still being continued till now. This should make 
the analysis of growth hormone therapy effects 
in different centers in the country possible. In this 
paper we aimed to share the results of our present 
treatment (from 1995), mainly because of continuity 
of both the therapy and observations.
Material and methods
The study comprised 117 children and adolescents 
aged 4.6 to 18.1 years, in whom either somato-
tropin alone or complete pituitary deficiency was 
diagnosed. There were 84 boys and 33 girls in study 
group. The diagnosis of growth hormone deficiency 
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was made based on two different stimulation tests 
(insulin challenge – 0.1-0.15 IU/kg body weight; 
Clonidine challenge – 100-150 µg/m2 body surface) 
that allowed for evaluation of the pituitary reserve 
[2, 3, 5, 6, 7, 8]. In patients diagnosed with multi-
hormonal pituitary deficiency, other hormonal 
deficiencies were taken care of, before the treatment 
with growth hormone was instituted. All patients 
received growth hormone: Genotropin 16 IU, 36 IU 
(Pharmacia-UpJohn), Norditropin Pen Set 12 and 
24 (Novo Nordisk), Serono 10 IU (Serono). Each of 
those growth hormone preparations was used for the 
same duration of time. The 0.5 IU/kg body weight/
week dosage was used in daily evening injections. 
Constant change of the administration site was used. 
The drugs were given with semiautomatic dosers, 
as advised by manufacturers. The growth rate was 
measured with standiometer Holtain type (Holtain 
Limited, Crymych, Dyfed; 1 mm accuracy). The 
body weight was estimated always with the same 
scale. The dose of the growth hormone was corrected 
according to body weight every three months. With 
the same frequency the thyroid function was deter-
mined (TSH, FT4 – radioassays). The development 
was ascertained based on Tanner scale. We assumed 
the drop in mean yearly growth rate below 1 cm/
year as the end of growth period. It was evaluated 
during two subsequent visits (six months apart), 
and complete epiphyseal ossification of long bones 
occurred, which was judged on the X-ray picture of 
the non-dominant upper extremity (hand and distal 
forearm section). For estimation of bone age the 
Greulich and Pyle method was used.
Results
The mean chronological age (CA) at the diagnosis of 
somatotropin deficiency and institution of growth 
hormone therapy was 13 years. In girls the diagnosis 
was made on an average a year earlier (12.6 years) 
than in boys (13.6 years). The bone age (BA) at the 
diagnosis was considerably lagging compared to 
chronological age. This lag was about 4 years, and 
was slightly higher in girls (-4.3 years). The bone 
age delay in boys was -3.9 years. This difference was 
statistically non significant. The above mentioned 
data are depicted in Table I.
The growth insufficiency before treatment was 
on an average -2.82 standard deviations (hSDS) 
and was slightly higher in boys than in girls. After 
correcting for paternal height (mpSDS) this growth 
lag declined to -1.47 standard deviations. This data 
is presented in Table II.
Table II. The growth lag in children and adolescents with 
pituitary insufficiency corrected for parental height before 
the start of growth hormone treatment.
Sex hSDS mpSDS hSDS-mpSDS
Girls -2.76 -1.49 -1.27
Boys -2.84 -1.06 -1.53
Whole studied 
group -2.82 -1.16 -1.47
Growth rate before treatment, measured in the 
last six months was 3.35 cm/year and was slightly 
higher for boys (3.5 cm/year) than in girls (3.2 cm/
year). Girls lacking the secondary sex characteristics 
grew noticeably slower than those in whom this 
development has already occurred. This difference 
was almost unnoticeable in boys – Table III.
Table III. The growth rate in patients with pituitary 
insufficiency before growth hormone treatment (cm/year).
Sex Growth rate
Growth rate 
without secondary 
sex characteristics
Growth rate with 
secondary sex 
characteristics
Girls 3.20 2.40 3.40
Boys 3.50 3.40 3.40
Whole 
group 3.35 2.90 3.40
After the start of growth hormone therapy 
during first six months, the growth rate rose notice-
ably achieving 10.4 cm/year in boys and 10.0 cm/
year in girls. During this period the growth rate 
was independent of the presence of the secondary 
sex characteristics and was the same for both sexes 
– Table IV.
Table IV. The growth rate during first six months of 
growth hormone therapy (cm/year)
Sex Growth rate
Growth rate before 
development of 
secondary sex 
characteristics
Growth rate during 
development of 
secondary sex 
characteristics
Girls 10.70 10.80 10.10
Boys 10.40 10.60 10.20
Whole 
group 10.55 10.70 10.15
Table I. The characteristic of studied group, children and adolescent with somatotropin and multihormonal pituitary 
deficiency.
Sex Number of studied patients
Chronological age - 
beginning of treatment
Bone age - beginning 
of treatment
Bone age delay
(CA-BA)
Girls 33 12.60 8.30 -4.30
Boys 84 13.60 9.70 -3.90
Whole group 117 13,00 9,00 -4,10
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In the second half of the year the growth rate 
declined somewhat and was 10.0 cm/year for girls 
and 9.8 for boys. The difference in growth rate influ-
enced by the presence or lack of the development of 
secondary sex characteristics, turned to be statisti-
cally insignificant – Table V.
Table V. The growth rate in second half of the year during 
growth hormone therapy (cm/year)
Sex Growth rate
Growth rate before 
development of 
secondary sex 
characteristics
Growth rate during 
development of 
secondary sex 
characteristics
Girls 10.00 10.10 9.90
Boys 9.80 9.60 10.30
Whole 
group 9.90 9.70 10.10
During further years of the study the growth rate 
was markedly lower, especially in girls – Table VI.
Table VI. The growth rate during growth hormone 
therapy after the first year of treatment (cm/year)
Sex Growth rate
Growth rate before 
development of 
secondary sex 
characteristics
Growth rate during 
development of 
secondary sex 
characteristics
Girls 6.60 7.20 6.20
Boys 8.20 7.80 8.60
Whole 
group 7.40 7.50 7.40
Some of the patients receiving growth hormone 
therapy have already finished their treatment. 
Their final achieved height in 93% of cases was in 
agreement with the estimated growth prognosis 
FH SDS-TH SDS= -0.5 (where FH SDS – standard 
deviation for final height, TH SDS – standard 
deviation for expected height). The mean growth 
deficiency at the termination of treatment was (-) 
0.5 standard deviations compared to expected value 
based on paternal height. It proves that during 
growth hormone therapy the achieved height 
improved nearly one standard deviation. Compared 
to population mean, the final height deficiency was 
(-) 1.34 standard deviations. Mean chronological 
age at termination of treatment was 17.1 years (±1.3) 
for women and 18.6 years (±1.16) for men.
Discussion
In present days treatment of somatotropin deficiency 
doesn’t confer a problem. Since 1958 when Raben 
extracted for the first time human growth hormone, 
the algorithm of injections evolved quite consi-
derably [1]. Preparations of biosynthetic growth 
hormone – methionyl-hGH, appeared during the 
80’, acquired by plasmid exchange containing 
somatotropin gene substituted in Escherichia coli 
and also in culture of mammal tissues [1, 2]. Since 
then the growth hormone found its use in many 
diseases, however it is still the mainstay of somato-
tropin pituitary deficiency treatment [9, 10].
The lack of growth hormone can have different 
etiologies and can have various effects, ranging 
from complete lack of secretion to only partial 
pituitary deficiency. In both cases the growth 
hormone therapy will provide some benefits, but 
as diverse are the treated groups as different will 
be the results. We have tried to compile the treated 
group in such way that it should not have influ-
enced the results. For study purposes we have 
only selected those patients in whom we have 
recognized somatotropin pituitary deficiency with 
idiopathic origin, or with perinatal insult in whom 
only partial secretion was preserved, and they have 
had the levels of GH within limits to warrant such 
a diagnosis [11]. From the study we have excluded 
all patients in whom the somatotropin deficiency 
occurred after pituitary removal, and there was a 
total lack of hormone secretion.
Second important element of treatment was 
establishing the schematic of growth hormone 
therapy regimen in which daily subcutaneous 
injections were performed, what is considered 
now a gold standard, contrary to what was used 
in previous years [1, 2, 3, 12]. Some doubts could 
arise as far as the optimal dosage of the growth 
hormone therapy. It is widely assumed that the 
therapeutic dose is comprised within 0.3-1.0 IU/kg 
body weight/week [1]. In studies conducted in 
Japan it was proven that somatotropin doses higher 
than 0.5 IU/kg body weight/week produce a better 
growth rate in the first year of treatment, however 
the growth rates for doses 0.5-1.0-1.5 IU/kg body 
weight/week after first year did not differ statisti-
cally [13]. In a second study conducted by the same 
team it was noticed that if the treatment was started 
with the dose of 0.5 IU/kg body weight/week in 
the first year of treatment and then subsequently 
increased during further therapy, the end growth 
rate was even better [13]. Comparing the results 
of these two studies it was noticed that the results 
achieved were much better than those of a control 
group receiving for the whole time 0.5 IU/kg body 
weight/week [13]. Since the therapy is still ongoing 
the researchers cannot say so far, if such design of 
the growth hormone doses will give a better final 
height. It might turn out that the achieved results do 
not justify the costs.
In our study the therapy was conducted with 
constant dose throughout the whole treatment 
period. We used a dose of 0.5 IU/kg body weight/
week divided into daily injections. Despite the 
constant dose the end result in 93% of cases was 
not different from estimated final height (FH (Final 
Height) SDS – TH (Target Height) SDS= -0.53). 
Similar favorable results were achieved during 
growth hormone treatment in Belgium, where it 
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was found in over 87% of patients [14]. The results 
achieved by us are very good in view of the fact that, 
according to Swedish studies, only 75% of patients 
treated with growth hormone for IGHD (idiopa-
thic growth hormone deficiency) achieved normal 
height, and the norms in that study were almost 
identical to our observations [15, 16]. However, 
there are some independent studies suggesting 
that the main determinant influencing the height 
achieved during growth hormone therapy is the 
parental height [17, 18, 19, 20, 21, 22]. From Polish 
observations one can only base the conclusion upon 
Romer studies and the achieved final results of 
treatment [1]. He concludes that, before 1993, the 
final height of patients receiving growth hormone 
therapy compared to patients receiving no therapy, 
improved by four standard deviations. At the same 
time only 50% of subjects reached lower threshold 
values. The rest remained within 3rd percentile. 
According to Romer the reason for such situation 
could be associated with the delay in beginning 
and disruption at conducted therapy [1]. Such 
conclusions could suggest that there is no reason 
for introducing higher doses of growth hormone 
in such patients in subsequent years. This pheno-
menon was seen both in girls and in boys. It is also 
worth noticing that, in Polish settings, important 
factor influencing the final height achieved during 
growth hormone therapy is the time of making the 
diagnosis and therefore instituting treatment. In 
our study the mean chronological age at admini-
stering the treatment was 12.6 years for girls and 
13.6 years for boys. It seems that this is too late for 
beginning of the therapy (Table 1). At the same time 
the bone age development was delayed 4 years, and 
the mean bone age was 9 years, what is influenced 
by the disease itself, but also leaves more time for 
treatment and improves the final height achieved. 
It is known from the literature that at the start of 
the growth hormone therapy its effects correlate 
inversely with the age of the patients, their height, 
weight and the advancement of bone development 
[2, 3, 23]. During a study conducted on nearly 400 
subjects with IGHD (idiopathic growth hormone 
deficiency) (KIGS-Pharmacia-UpJohn International 
Growth Database) it was proven that commonly 
dosed growth hormone therapy leads to achieve-
ment of normal height estimated from parental 
mean height. On the other hand it is believed, that 
introducing higher doses or individual doses might 
be necessary for those patients with IGHD, who are 
underprivileged because of late therapy initiation 
or low parental height [15]. So, those 7% of patients 
treated by us, in whom the final achieved height was 
not totally satisfactory, might require individualiza-
tion of the doses at subsequent therapy. One has to 
remember that higher doses of growth hormone 
might speed up the maturation and its intensity, 
leading ultimately to shortening of the growth 
period [4]. Yet, according to Japanese studies, higher 
doses of growth hormone do not lead to expediting 
of the “closure” of the long bones’ epiphyseal plate 
[13]. This problem will surely require further eluci-
dation. It is however a fact, that better final growth 
is achieved by those patients who mature later [24].
The mean growth rate observed by us during 
first six months of treatment was 10.5 cm/year 
(Table IV). Compared to growth rate achieved by 
our patients before instituting the treatment we 
observed nearly 3 times improvement. Dash believes 
that during first year of therapy the mean growth 
rate is 6-8 cm/year [10]. This growth rate is in 
agreement with commonly described phenomenon 
observed at the beginning of therapy – the so-called 
“catch up” [1]. It is thought that achieved at that 
time acceleration of growth pattern correlates well 
with the initial growth lag, so the highest growth 
rate will be observed in those patients in whom the 
height lag was the greatest [20, 23, 25]. Also Sudfeld 
thinks that the main factor influencing the growth 
rate in the first year of treatment is the difference 
between expected height and the height deficiency 
at the beginning of therapy [25]. Similarly better 
effects of treatment will be achieved in patients with 
complete pituitary insufficiency than in those with 
only partial problem [26]. In conclusion, it seems 
that in our experiment choosing patients with only 
partial pituitary deficiency might have influenced 
the growth rate of our patients. Another point – at 
the beginning of therapy the mean growth lag was 
2.8 standard deviations (hSDS), and after correc-
tion for parental height it was only -1.5 (Table II). 
The worse prognosis for the expected growth rate 
should be stressed here, caused by lack of growth 
potential [23]. In our study the growth rate at 
the second half year was only slightly lower and 
achieved 9.9 cm/year (Table V). It is difficult to 
strictly determine the duration of the “catch up” 
phenomenon. It is thought that it might last few 
or even 12 months after the beginning with growth 
hormone treatment. Most frequently it is estimated 
to last for half a year [1, 2]. In subsequent years of 
therapy, after the first year, the growth rate declined 
markedly and was 7.4 cm/year. This phenomenon 
is commonly observed. It is assumed that achieved 
growth speed during this time is equivalent to 
natural growth rate. However it is difficult to explain 
the similarity in growth rate of patients treated with 
growth hormone for at least a year, regardless of 
the development stage (Table VI). This could be 
only a coincidence, caused by increase in number of 
patients in whom the development process already 
lasted for same time, and the growth rate associated 
with this process already begun to show declining 
tendency associated with the approaching of the 
expected final height. The growth rate observed in 
patients without any signs of development seems 
similar to those observed in other studies.
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The results of our study, especially the final 
height, are very optimistic effects of our therapeutic 
efforts. However it should be stressed that there is 
a potential for further improvement of our results. 
This could be achieved by lowering the age of initial 
diagnosis of somatotropin pituitary deficiency, so 
that the younger age could allow for lengthening 
of the growth hormone treatment duration [22, 27]. 
It also seems important to individualize, in some 
cases, the doses of the growth hormone.
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